Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
Go back to Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 38.37 +1.59 (4.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.78 | 52 Week High | $18.62 | |||
| Open | $36.95 | 52 Week Low | $2.85 | |||
| Day High | $38.43 | P/E | N/A | |||
| Day Low | $36.18 | EPS | $-1.02 | |||
| Volume | 1,037,328 | |||||
